Scientists are claiming significant success in targeting a specific type of blood cancer with engineered immune cells in their first clinical trials. Among several dozen patients who would typically possess only had months to live,early experimental trials that used the immune system’s T-cells to target cancers had ‘extraordinary results’. However, the availability of the treatment is still years awayContinue reading...
Source: theguardian.com